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CASE REPORT
Significant improvement of risperidone-induced retrograde ejaculation on
drug holidays: a case report
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aMental Health Research Center, Iran University of Medical Sciences, Tehran, Iran; bPediatric Endocrinology and Metabolism Department of
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ABSTRACT
Risperidone, which is one of the most commonly prescribed second-generation antipsychotics
can cause several sexual adverse effects. To date, research on the sexual side effects of
risperidone has been mostly restricted to symptoms of decreased libido, erectile dysfunction
and delayed ejaculation and far too little attention has been paid to risperidone associated
retrograde ejaculation. What is not clear is that whether this side effect appears in a dose-
dependent manner and whether structured treatment interruptions/drug holidays can
diminish sexual adverse effects without a reduction in treatment efficacy. Another question is
whether concurrent use of opiates and risperidone can increase the risk of retrograde
ejaculation due to their anticholinergic and adrenergic blocking properties. Here we describe
a case of a 30-year-old male with schizophrenia and opium dependence who developed
risperidone-induced retrograde ejaculation; however, the ejaculatory dysfunction improved
significantly on drug holidays. This is the first report on the use of structured treatment
interruptions in the management of risperidone-induced retrograde ejaculation.
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Risperidone is one of the most widely used second-
generation antipsychotics in clinical practice. It is
approved for the treatment of schizophrenia, bipolar
disorder and behavioural disturbances in children
and adolescents with autistic spectrum disorders. It is
also effectively used to treat other psychotic disorders,
including schizoaffective and delusional disorder,
psychotic disorder due to another medical condition,
substance-induced psychotic disorder, depressive
disorder with psychotic features and behavioural
symptoms in neurocognitive disorder [1]. Risperidone
inhibits dopaminergic D2 receptors, serotonergic 5-
HT2A receptors and alpha-adrenergic receptors,
while it is considered to have minimal anticholinergic
effects [2]. Despite its efficacy, risperidone has several
adverse effects including extrapyramidal effects, dizzi-
ness and metabolic disturbances as well as sexual side
effects [3].
To date, research on the sexual side effects of ris-
peridone has been mostly restricted to symptoms of
decreased libido, erectile dysfunction and delayed eja-
culation and far too little attention has been paid to
risperidone associated retrograde ejaculation.
Recently, few studies have reported the occurrence
of retrograde ejaculation associated with risperidone
use resulting in a negative effect on treatment compli-
ance [4–6]. What is not clear is that whether this side
effect appears in a dose-dependent manner and
whether structured treatment interruptions/drug holi-
days can diminish sexual adverse effects without a
reduction in treatment efficacy.
In addition, a number of studies have reported eja-
culatory disturbances noted in chronic opiate users
[7,8]. The question is whether concurrent use of opiates
and risperidone can increase the risk of retrograde eja-
culation due to their anticholinergic and antiadrenergic
effects.
Here we describe a case of a 30-year-old male with
schizophrenia and opium dependence who developed
risperidone-induced retrograde ejaculation; however,
the ejaculatory dysfunction improved significantly on
drug holidays.
Case presentation
The patient was a 30-year-old male referred to the hos-
pital with a 1-year history of psychotic symptoms such
as running commentary auditory hallucinations, tran-
sient visual hallucinations and persecutory delusions.
He also suffered from insomnia, dysphoric mood and
impaired social function; however, he did not experi-
ence suicidal or homicidal thoughts. He had no pre-
vious history of active psychiatric treatment or
admission to a psychiatric ward or hospital. He did
not report any history of medical illness including gen-
itourinary surgery, diabetes mellitus or neurological
injuries. There was no previous history of ejaculatory
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dysfunction. The patient had not taken any medication
for at least six months before his first visit. He reported
an active period of problematic methamphetamine and
cannabis use for about five years, followed by a period
of partial abstinence over the past five years. He
smoked about two grams of opium every day, since 4
years ago. He had some pathologic personality traits
such as impulsivity, risky behaviours and intolerability
but he did not meet criteria for any specific personality
disorder. His physical examination including a
thorough neurological assessment was unremarkable.
Considering the course of psychotic symptoms, a
diagnosis of schizophrenia was made according to
DSM-51 criteria [9]. The oral form of risperidone was
initiated and the dose was titrated gradually to 6 mg/
day over 2 weeks. As mentioned above, the patient
smoked about two grams of opium every day, since 4
years ago and he did not change the amount or route
of opium use during treatment with risperidone.
Although psychotic symptoms responded well to ris-
peridone, the patient developed the manifestations of
retrograde ejaculation including dry orgasm and
cloudy urine when the dose of 6 mg/day was reached.
The patient received a comprehensive medical workup
including a thorough urologic examination. The diag-
nosis of retrograde ejaculation was confirmed by the
urologist and possible structural causes for ejaculatory
dysfunction were ruled out. In spite of retrograde eja-
culation, he had normal sexual desire and adequate
erectile function. On the laboratory work up; serum
prolactin level was in normal range and the patient
didn`t show any manifestations of hyperprolactinemia.
The side effect of retrograde ejaculation was suspected
to be associated with the use of risperidone, however
decreasing the dose of risperidone was not helpful
and a switch to perphenazine (24 mg/day) resolved
the sexual dysfunction, but nevertheless, psychotic
symptoms returned after 2 weeks.
Finally, perphenazine was discontinued and risperi-
done was started again and weekend drug holidays
were planned in order to reduce the symptom of ejacu-
latory dysfunction. The omission of risperidone on
weekends (i.e. withdrawal of the medication each
Thursday and Friday) led to improved ejaculatory
function during weekends without a clinically signifi-
cant reduction in treatment efficacy, although ejacula-
tory problems were still bothering during the rest of
the week. Overall the treatment plan was effective
and tolerable for the patient during the 6-month fol-
low-up period.
Discussion
This is the first report on the use of structured treatment
interruptions for the management of risperidone-
induced retrograde ejaculation. We reported a patient
with schizophrenia and opioid dependence who
experienced retrograde ejaculation during risperidone
treatment. Retrograde ejaculation refers to the failure
of the semen to be ejected out through the urethra.
The semen is refluxed into the urine bladder as a result
of inadequate bladder neck closure. Throughout normal
ejaculation, sympathetic system maintains closure of
the bladder neck to prevent retrograde flow of semen.
Partial or complete loss of sympathetic input to the
smooth muscles of the bladder neck can lead to retro-
grade ejaculation [10]. This condition can occur as a
result of neurogenic or anatomic abnormalities or may
be associated with the use of various medications [11].
Several studies thus far have revealed that postsynaptic
antagonism of the alpha1 adrenergic receptor is impli-
cated in developing retrograde ejaculation by altering
the sympathetic tonus of the bladder or urethral sphinc-
ter [12]. Therefore, it has been suggested that risperi-
done which has potent alpha1 adrenergic blocking
effects may cause retrograde ejaculation by a similar
mechanism [13]. Till now a few number of cases of ris-
peridone-induced retrograde ejaculation have been
reported [4–6]. In contrast to previously reported
cases, in which retrograde ejaculation was related to a
rapid dose increase, our patient developed ejaculatory
dysfunction with gradual dose titration of risperidone.
Therefore, it seems likely that this sexual adverse effect
is not related to the rate of increase in the dose of risper-
idone. Moreover, in our case, contrary to those pre-
viously published, the ejaculatory problem did not
resolve with the reduction of the risperidone dose and
thus the ejaculatory dysfunction may not be a dose-
dependent phenomenon. Interestingly, the omission
of risperidone on weekends resulted in a remarkable
reduction of sexual side effects and the patient had an
adequate ejaculatory function on drug holidays without
a clinically significant reduction in efficacy of antipsy-
chotic therapy. This finding has an important clinical
implication with regard to medication adherence in
patients; however, further investigations are required
to specifically address the effectiveness of drug holidays
during risperidone treatment.
It is also important to note that our patient’s serum
prolactin level was within the normal range and he did
not experience any clinical manifestations of hyperpro-
lactinemia during treatment with risperidone. It can
thus be suggested that the development of retrograde
ejaculation was most probably due to alpha1 adrenergic
blockade and was not related to elevated prolactin level.
As was pointed out in the introduction to this paper,
a number of researchers have reported ejaculatory dis-
turbances noted in chronic opiate users [7,8]. Opiates
can lead to ejaculatory dysfunction through hypo-
gonadal and androgen-inhibiting effects as well as
blockade of alpha-adrenergic, cholinergic and opioid
receptors in the ejaculatory circuit [14]. It is note-
worthy that the patient described here did not change
his pattern and amount of opium use during treatment,
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therefore, it seems unlikely that the ejaculatory dys-
function was merely due to opium use. However, it
can be assumed that in our patient, concurrent use of
opium and risperidone severely interrupted normal
ejaculatory function and possibly exacerbated retro-
grade ejaculation.
Taken together, this case report aims to convey two
clinical messages. First, risperidone-induced retrograde
ejaculation is possibly unrelated to dose. Secondly, per-
forming structured treatment interruptions can result
in a remarkable reduction of sexual side effects without
a clinically significant reduction in treatment efficacy.
This report provides new insights into the management
of retrograde ejaculation associated with risperidone
and perhaps other antipsychotics. We also considered
the greater likelihood of risperidone-induced retro-
grade ejaculation when opiates are used concurrently.
Note
1. Diagnostic and Statistical Manual of Mental Dis-
orders, Fifth Edition.
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